Author

Tara Basavanhally

Observed names: T. Basavanhally, Tara J. Basavanhally

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5000141165

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels

2022 · Lizhi Yu, Gonzalo Lopez, et al. · PLoS ONE · 26

Autoimmune gene expression profiling of fingerstick whole blood in Chronic Fatigue Syndrome

2022 · Zheng Wang, Michelle F. Waldman, et al. · Journal of Translational Medicine · 11

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

2024 · Arnaud Amzallag, Tara Basavanhally, et al. · Blood · 6

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways

2026 · Hsiling Chiu, Junfei Zhao, et al. · Blood · 4

ABCL-503 Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

2024 · Jason Westin, Marc S. Hoffmann, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

2023 · Mark Kaplan, Tara Basavanhally, et al. · Blood · 1

2467P Higher circulating tumor DNA levels in chemo-experienced mCRPC patients serve as a poor prognostic marker for checkpoint inhibitors (CI) or chemo therapy: A post hoc analysis of CM 650

2025 · P. Sharma, S. Gupta, et al. · Annals of Oncology

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-Line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

2024 · Jason Westin, Marc S. Hoffmann, et al. · Clinical Lymphoma Myeloma & Leukemia

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

2024 · Jason Westin, Marc S. Hoffmann, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 9

Citation count: 49

H-index: 4

I10-index: 2